We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

DNA Biomarkers in Tissue Samples From Patients With Osteosarcoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01190943
Recruitment Status : Active, not recruiting
First Posted : August 30, 2010
Last Update Posted : October 9, 2017
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Children's Oncology Group

August 27, 2010
August 30, 2010
October 9, 2017
August 2010
January 2100   (Final data collection date for primary outcome measure)
Identification and validation of biomarkers with potential clinical utility
Same as current
Complete list of historical versions of study NCT01190943 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
DNA Biomarkers in Tissue Samples From Patients With Osteosarcoma
Therapeutically Applicable Research to Generate Effective Treatments (TARGET) for Osteosarcoma

RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes the occur in DNA and identify biomarkers related to cancer. DNA analysis of tumor tissue may also help doctors predict how well patients will respond to treatment.

PURPOSE: This research study is studying DNA biomarkers in tissue samples from patients with osteosarcoma.


  • To comprehensively detect genomic, epigenomic, and transcriptomic aberrations in tissue samples from patients with osteosarcoma that may play a role in chemoresistance and metastasis using high-resolution genome-wide technologies.
  • To identify recurrent genetic mutations involved in the pathogenesis of osteosarcoma, especially for the development of chemoresistance and metastatic tumors.
  • To identify and validate these biomarkers for new therapeutic targets for patients with osteosarcoma, especially those with metastatic disease and whose tumors are resistant to standard chemotherapy.

OUTLINE: This is a multicenter study.

Archived tumor tissue and peripheral blood DNA specimens are analyzed for DNA copy number profiling, gene expression profiling, DNA methylation profiling, microRNA profiling, and genomic resequencing. Clinical data including demographics; date of diagnosis, surgery, chemotherapy, recurrence, progression, and death; imaging; toxicity; and pathologic data elements associated with the specimens are also collected and analyzed.

Observational Model: Case-Only
Time Perspective: Retrospective
Not Provided
Retention:   Samples With DNA
Non-Probability Sample
Patients With Osteosarcoma
  • Genetic: DNA methylation analysis
  • Genetic: RNA analysis
  • Genetic: comparative genomic hybridization
  • Genetic: gene expression analysis
  • Genetic: microarray analysis
  • Genetic: mutation analysis
  • Other: laboratory biomarker analysis
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Active, not recruiting
Not Provided
January 2100   (Final data collection date for primary outcome measure)


  • Diagnosis of osteosarcoma
  • Fresh-frozen samples collected at the time of diagnosis with matched blood DNA (preferred) from patients enrolled on the following osteosarcoma biology protocols:

    • COG-P9851
    • COG-AOST06B1
  • Available clinical outcome data


  • Not specified


  • Not specified
Sexes Eligible for Study: All
up to 120 Years   (Child, Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
COG-AOST10B5 ( Other Identifier: Children's Oncology Group )
NCI-2011-02840 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
AOST10B5 ( Other Identifier: Children's Oncology Group )
Not Provided
Not Provided
Children's Oncology Group
Children's Oncology Group
National Cancer Institute (NCI)
Principal Investigator: Ching C. Lau, MD, PhD Texas Children's Cancer Center
Children's Oncology Group
October 2017